Affordable Access

High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study

  • cordova-delgado, miguel
  • pinto, mauricio p.
  • retamal, ignacio n.
  • muñoz-medel, matías
  • bravo, maría loreto
  • fernández, maría f.
  • cisternas, betzabé
  • mondaca, sebastián
  • sanchez, césar
  • galindo, hector
  • nervi, bruno
  • ibáñez, carolina
  • acevedo, francisco
  • madrid, jorge
  • peña, josé
  • koch, erica
  • maturana, maria josé
  • romero, diego
  • de la jara, nathaly
  • torres, javiera
  • And 17 more
Publication Date
Aug 30, 2019
External links


n = 101). Most demographic and clinical data were in line with previous reports. TMA data indicated that 60% of patients displayed potentially actionable alterations. Furthermore, 20.5% were categorized as having a high tumor mutational burden, and 13% possessed micro-satellite instability (MSI). Results also confirmed previous studies reporting high Epstein-Barr virus (EBV) positivity (13%) in Chilean-derived GC samples suggesting a high proportion of patients could benefit from immunotherapy. As expected, TP53 and PIK3CA were the most frequently altered genes. However, NGS demonstrated the presence of TP53, NRAS, and BRAF variants previously unreported in current GC databases. Finally, using the Kendall method, we report a significant correlation between EBV+ status and programmed death ligand-1 (PDL1)+ and an inverse correlation between p53 mutational status and MSI. Our results suggest that in this Chilean cohort, a high proportion of patients are potential candidates for immunotherapy treatment. To the best of our knowledge, this study is the first in South America to assess the prevalence of actionable targets and to examine a molecular profile of GC patients.

Report this publication


Seen <100 times